Chemotherapy for intracranial ependymoma in adults

BMC Cancer. 2016 Apr 23:16:287. doi: 10.1186/s12885-016-2323-0.


Background: Ependymal tumors in adults are rare, accounting for less than 4% of primary tumors of the central nervous system in this age group. The low prevalence of intracranial ependymoma in adults limits the ability to perform clinical trials. Therefore, treatment decisions are based on small, mostly retrospective studies and the role of chemotherapy has remained unclear.

Methods: We performed a retrospective study on 17 adult patients diagnosed with intracranial World Health Organisation grade II or III ependymoma, who were treated with chemotherapy at any time during the disease course. Benefit from chemotherapy was estimated by applying Macdonald criteria. Progression-free (PFS) and overall survival (OS) were calculated from start of chemotherapy, using the Kaplan-Meier method.

Results: Eleven patients had supratentorial and 6 infratentorial tumors. Ten patients were treated with temozolomide (TMZ), 3 with procarbazine/lomustine/vincristine (PCV), 3 with platinum-based chemotherapy and 1 patient received epirubicin/ifosfamide. Response rates were as follows: TMZ 8/10 stable disease; PCV 3/3 stable disease; platinum-based chemotherapy 1/3 partial response; epirubicin/ifosfamide 1/1 complete response. PFS rates at 6, 12 and 24 months were 52.9, 35.3 and 23.5%. OS rates at 6, 12 and 24 months were 82.4, 82.4 and 70.1%. There was no indication for a favourable prognostic role of O(6)-methylguanyl-DNA-methyltransferase (MGMT) promoter methylation which was detected in 3/12 investigated tumors.

Conclusions: Survival outcomes in response to chemotherapy in adult intracranial ependymoma patients vary substantially, but individual patients may respond to any kind of chemotherapy. There were too few patients to compare survival data between chemotherapeutic subgroups.

Keywords: Adults; Chemotherapy; Intracranial ependymoma; Overall survival; Progression-free survival.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / pathology
  • Dacarbazine / administration & dosage
  • Dacarbazine / analogs & derivatives*
  • Disease-Free Survival
  • Ependymoma / drug therapy*
  • Ependymoma / pathology
  • Epirubicin / administration & dosage
  • Female
  • Humans
  • Ifosfamide / administration & dosage
  • Kaplan-Meier Estimate
  • Lomustine / administration & dosage
  • Male
  • Middle Aged
  • Procarbazine / administration & dosage
  • Temozolomide
  • Treatment Outcome
  • Vincristine / administration & dosage


  • Procarbazine
  • Epirubicin
  • Vincristine
  • Lomustine
  • Dacarbazine
  • Ifosfamide
  • Temozolomide

Supplementary concepts

  • Familial ependymoma
  • PCV protocol